Open Source COVID-19 Drug Discovery Group (OSC19)

Organization and Membership

OSC19 mission

OSC19 is dedicated to advancing drug discovery research for COVID19 for humanitarian aims. All results and data will be shared openly as much as possible. OSC19 will make no intellectual property claims and will not pursue patents. OSC19 members and the public may use OSC19 data and results for academic or commercial purposes provided OSC19 is credited.

Research plans

We are currently focused on small molecule drug discovery for SARS-CoV-2 targets. We have particular expertise with computational and structure-based drug design although we are not limited to these techniques. We are currently working on the targets Mpro protease, nsp16 RNA methyltransferase, Spike protein, nsp15 endoribonuclease, and RNA polymerase. We are currently focused on repurposing known drugs and chemical reagents and investigating their close chemical analogs. Our research capabilities include computational screening, AI drug discovery, molecular dynamics simulations, chemical synthesis, biochemical and biophysical assays, X-ray crystallography, and in vitro BSL3 viral assays.

Senior Members (Lab heads)

Ho Leung Ng, Founder
Associate Professor of Biochemistry & Biophysics, Kansas State University, USA
Computational and experimental structure-based drug design. AI-driven drug design.

Michael Scott Long
Professional science writer
OSC19 writer and social media director. PhD in analytical chemistry.

Yousef Najajreh
Associate Professor and Dean, Al-Quds University Faculty of Pharmacy, Palestine
Medicinal chemistry.

Abraham Karlapudi Peele
Assistant Professor of Biotechnology, Vignan’s Foundation University, India
Computational drug design.

UC Jaleel
Principal Investigator, CSIR-Open Source Drug Discovery, India

Mohsin Tariq
Data Scientist, National Center in Big Data and Cloud Computing, Pakistan
Data science.

Troy Messick
Senior Staff Scientist, Wistar Institute, USA
Biochemistry, assays, and crystallography for Mpro protease.

Venkatesh Natarajan
Assistant Professor, University of Southern California Keck School of Medicine, USA
Biochemistry and drug discovery.

Harry Ridgway
Owner, AquaMem Scientific Consultants, USA
Computational chemistry

Prakasha Kempaiah
Associate Professor, Loyola University Stritch School of Medicine, USA
Biochemistry, computational drug design, assays, medicinal chemistry, epidemiology.

Patrick St-Amant
Chief Technical Officer, Zetane Systems
AI drug discovery.


SSGCID (Seattle Structural Genomics Center for Infectious Diseases), USA
Assays, protein expression, crystallography. Targets: nsp14, nsp15, nsp16.

Alan Aspuru-Guzik
Professor of Chemistry and Computer Science, University of Toronto, Canada
AI drug discovery, assays, computational chemistry, synthetic chemistry. Target: nsp16.

Jurgen Richt
Professor, Kansas State University College of Veterinary Medicine, Director of the Center of Excellence for Emerging and Zoonotic Animal Diseases, USA
BSL3 SARS-CoV-2 viral assays.

Intel, USA
Sponsor. DevCloud cloud computing. Intel software tools.

Hypernet, USA
Cloud computing resources for scientific computing.

Dongbang FTL, South Korea
Synthetic chemistry.

Gapibio, South Korea
Synthetic chemistry.

Open Source Pharma Foundation, India/USA
Pioneer in open source drug discovery and development. Advisory.

Pharmacelera, Spain
Computational drug screening software.

Create your website with
Get started
%d bloggers like this: